Captopril是近年来新合成的口服血管紧张素Ⅰ转换酶之抑制剂(AⅠ·CEⅠ),国内外应用治疗高血压和顽固性充血性心衰,疗效显著,作用持久,不良反应较少,值得推广应用。作用机理:Captopril能与AⅠ或缓激肽竞争AⅠ·CE.本药的化学结构类似于AⅠ·CE,有强烈的抑制AⅠ转换为AⅡ的作用,从而使体循环血管阻力降低,减轻心脏后负荷,明显改善心功能,其降压作用还与延缓缓激肽降解,使血浆和组织内缓激肽积蓄而致血管扩张有关。服用本药可见静脉扩张,原因尚未阐明,但可降低前负荷,本药还可抑制醛固酮的形成,增加肾脏水钠排泄,而且能减轻一般血管扩张剂、洋地黄及 Captopril, a newly synthesized inhibitor of oral angiotensin I converting enzyme (AⅠ · CEⅠ), has been used in the treatment of hypertension and refractory congestive heart failure both at home and abroad with significant curative effect, long lasting effect and few adverse reactions and is worth promoting application. Mechanism of Action: Captopril competes with AⅠ or bradykinin for AⅠ · CE. The chemical structure of this drug is similar to AⅠ · CE and has a strong inhibitory effect on the conversion of AⅠ to AⅡ, thereby reducing systemic vascular resistance and reducing post-cardiac load, Significantly improve cardiac function, and its antihypertensive effect is also delayed and bradykinin degradation, so that plasma and tissue accumulation of bradykinin caused by vasodilation related. Taking this drug can be seen venous dilatation, the reasons have not yet been clarified, but can reduce the preload, the drug can inhibit the formation of aldosterone and increase renal sodium excretion of water, but also reduce the general vasodilators, digitalis and digitalis